What is clinical trial NCT04227847 studying?

NCT04227847 is a Phase 1 clinical trial evaluating SEA-CD70 for Myelodysplastic Syndrome. The trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer and is currently active, not recruiting.

What phase is the NCT04227847 clinical trial?

NCT04227847 is a Phase 1 clinical trial. Phase 1 trials are early-stage safety and dosing studies in a small group, typically 20–80 people.

Is NCT04227847 still recruiting participants?

The current enrollment status of NCT04227847 is: Active, not recruiting. Enrollment is complete. The trial is in its data collection phase.

Who is the sponsor of clinical trial NCT04227847?

NCT04227847 is sponsored by Seagen, a wholly owned subsidiary of Pfizer (PFE). BiotechSign currently grades the sponsor a C (52/100) based on its composite pipeline strength and catalyst outlook.

Home›Trial›NCT04227847

NCT04227847Phase 1Active, not recruiting

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Study Summary

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with AML. * Part D will find out how much SEA-CD70 with azacitidine should be given to participants * Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is compared to azacitidine alone and if it works to treat participants with MDS or MDS/AML that has not been treated. * Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML. * Part G will find out how much SEA-CD70 with azacitidine and with venetoclax should be given to participants with AML. Also, to evaluate safety and tolerability of PF-08046040 in combination with azacitidine and venetoclax in participants with previously untreated AML who are unfit for standard induction chemotherapy.

Conditions

Myelodysplastic Syndrome Acute Myeloid Leukemia

Interventions / Drugs

SEA-CD70 azacitidine Venetoclax

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment170 participants

Primary Completion2027-07-04

Lead SponsorSeagen, a wholly owned subsidiary of Pfizer

Data Retrieved2026-10-14

What This Trial Means for Biotech Investors

Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Primary completion: 2027-07-04

Enrolled: 170 participants

Sponsor Catalyst Profile

Pfizer Inc (PFE) is the sponsoring company for this trial. BiotechSign currently grades this company C (52/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PFE Full Pipeline →All Companies →

Other Trials from Pfizer Inc

NCT05805826To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons…(PHASE1/PHASE2)NCT07215078Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure a…(PHASE1)NCT07363694A Study to Learn About the Study Medicine Called PF-07275315 in People With Mode…(PHASE2/PHASE3)NCT05571839A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors(PHASE1)NCT07222800Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in…(PHASE3)

Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.